Adebrelimab Clinical Trials

3 recruiting

Adebrelimab Trials at a Glance

6 actively recruiting trials for adebrelimab are listed on ClinicalTrialsFinder across 6 cities. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Tianjin, Beijing, and Nanjing. Lead sponsors running adebrelimab studies include Tianjin Medical University Cancer Institute and Hospital, Beijing Friendship Hospital, and The First Affiliated Hospital of Xiamen University.

Browse adebrelimab trials by phase

Treatments under study

About Adebrelimab Clinical Trials

Looking for clinical trials for Adebrelimab? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Adebrelimab trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Adebrelimab clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer

AdebrelimabAdenocarcinoma of GE JunctionAdenocarcinoma of Stomach
Beijing Friendship Hospital49 enrolled1 locationNCT07353684
Recruiting
Phase 2

Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE

Cholangiocarcinoma CancerAdebrelimab (SHR-1316)
The First Affiliated Hospital with Nanjing Medical University122 enrolled4 locationsNCT06607276
Recruiting
Phase 2

Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma

Hepatocellular CarcinomaAdebrelimab
Tianjin Medical University Cancer Institute and Hospital40 enrolled4 locationsNCT06405061
Recruiting
Phase 2

A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

Adebrelimab (SHR-1316)XELOXGC/GEJC
Tianjin Medical University Cancer Institute and Hospital25 enrolled1 locationNCT06506292
Recruiting
Phase 1Phase 2

Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer

Metastatic Pancreatic CancerAdebrelimab (SHR-1316)Decitabine
Tianjin Medical University Cancer Institute and Hospital20 enrolled1 locationNCT06454448
Recruiting
Phase 2

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular CarcinomaBevacizumabAdebrelimab+2 more
The First Affiliated Hospital of Xiamen University71 enrolled1 locationNCT05970666